The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Open accessAbstract
Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been identified in gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel enzymatic property of producing 2-hydroxyglutarate (2HG) from α-ketoglutarate. Here we report that 2HG-producing IDH mutants can prevent the histone demethylation that is required for lineage-specific progenitor cells to differentiate into terminally differentiated cells. In tumour samples from glioma patients, IDH mutations were associated with a distinct gene expression profile enriched for genes expressed in neural progenitor cells, and this was associated with increased histone methylation. To test whether the ability of IDH mutants to promote histone methylation contributes to a block in cell differentiation in non-transformed cells, we tested the effect of neomorphic IDH mutants on adipocyte differentiation in vitro. Introduction of either mutant IDH or cell-permeable 2HG was associated with repression of the inducible expression of lineage-specific differentiation genes and a block to differentiation. This correlated with a significant increase in repressive histone methylation marks without observable changes in promoter DNA methylation. Gliomas were found to have elevated levels of similar histone repressive marks. Stable transfection of a 2HG-producing mutant IDH into immortalized astrocytes resulted in progressive accumulation of histone methylation. Of the marks examined, increased H3K9 methylation reproducibly preceded a rise in DNA methylation as cells were passaged in culture. Furthermore, we found that the 2HG-inhibitable H3K9 demethylase KDM4C was induced during adipocyte differentiation, and that RNA-interference suppression of KDM4C was sufficient to block differentiation. Together these data demonstrate that 2HG can inhibit histone demethylation and that inhibition of histone demethylation can be sufficient to block the differentiation of non-transformed cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
In the citing paper
“In addition to its epigenetic effects, D-2HG inhibits enzymes from the canonical metabolic network (104). Such enzymes include transaminases that produce glutamate for glutathione biosynthesis, rendering IDH-mutant gliomas susceptible to treatments that deplete glutamate and enhance oxidative stress (105).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [104]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [118]
In the citing paper
“a neomorphic mutation in IDH1 and/or IDH2 causes a change in enzymatic activity and the accumulation of 2-hydroxyglutarate (2-HG), which inhibits the function of αKG-dependent enzymes such as TET2, resulting in the loss of 5hmC, an increase in DNA methylation and ultimately altered gene expression programmes that drive cancer development66.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [66]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [173]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
Self-citationFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citationIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
Self-citation
Cited by
Sorted by citations
Items 601–700 of 1,001
Therapeutic Targeting of Cancer Stem Cells: Integrating and Exploiting the Acidic Niche
Linden, C. V., & Corbet, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00159 · Cited by 58
Metabolism navigates neural cell fate in development, aging and neurodegeneration
Traxler, L., Lagerwall, J., Eichhorner, S., Stefanoni, D., D’Alessandro, A., & Mertens, J. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048993 · Cited by 59
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
Solomou, G., Finch, A., Asghar, A., & Bardella, C. (2023) · Cancers · doi:10.3390/cancers15112883 · Cited by 62
Metabolic Modulation of Epigenetics in Gliomas
Venneti, S., & Thompson, C. B. (2013) · Brain Pathology · doi:10.1111/bpa.12022 · Cited by 56
Self-citationMa, S., Jiang, B., Deng, W., Gu, Z.-K., Wu, F.-Z., Li, T., Xia, Y., Yang, H., Ye, D., Xiong, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3330 · Cited by 57
Metabolic interactions with cancer epigenetics
Gao, X., Reid, M. A., Kong, M., & Locasale, J. W. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.09.001 · Cited by 55
Ohba, S., Mukherjee, J., Johannessen, T.-C. A., Mancini, A., Chow, T. T., Wood, M. D., Jones, L. E., Mazor, T., Marshall, R. E., Viswanath, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0696 · Cited by 55
The interplay between metabolic remodeling and immune regulation in glioblastoma
Kesarwani, P., Kant, S., Prabhu, A. H., & Chinnaiyan, P. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox079 · Cited by 56
The metabolic axis of macrophage and immune cell polarization
Hobson-Gutierrez, S., & Carmona‐Fontaine, C. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.034462 · Cited by 57
Decoding the Rosetta stone of mitonuclear communication
English, J., Son, J. M., Cardamone, M. D., Lee, C., & Perissi, V. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105161 · Cited by 55
Metabolic circuits in neural stem cells
Kim, D., Rhee, I., & Paik, J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1686-0 · Cited by 59
Yoo, Y., PARK, J., Weigel, C., Liesenfeld, D. B., Weichenhan, D., Plass, C., Seo, D.-G., Lindroth, A. M., & Park, Y. J. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.8 · Cited by 53
The clinical use of IDH1 and IDH2 mutations in gliomas
Pïcca, A., Berzero, G., Stefano, A. L. D., & Sanson, M. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1548935 · Cited by 55
Genetic Events That Shape the Cancer Epigenome
Ryan, R. J. H., & Bernstein, B. (2012) · Science · doi:10.1126/science.1223730 · Cited by 55
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation
Hansen, L. J., Sun, R., Yang, R. R., Singh, S. X., Chen, L. H., Pirozzi, C. J., Moure, C. J., Hemphill, C., Carpenter, A. B., Healy, P. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1010 · Cited by 56
Mur, P., Mollejo, M., Ruano, Y., de Lope, Á. R., Fiaño, C., García, J. F., Castresana, J. S., Hernández‐Laín, A., REY, J. A., & Meléndez, B. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1130-9 · Cited by 54
Antagonistic functional duality of cancer genes
Stepanenko, A. A., Vassetzky, Y. S., & KAVSAN, V. M. (2013) · Gene · doi:10.1016/j.gene.2013.07.047 · Cited by 54
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma
Grassian, A. R., Pagliarini, R. A., & Chiang, D. Y. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000050 · Cited by 54
The good, the bad and the ugly: Epigenetic mechanisms in glioblastoma
Carén, H., Pollard, S. M., & Beck, S. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.007 · Cited by 55
Myeloproliferative neoplasms: from origins to outcomes
Nangalia, J., & Green, A. R. (2017) · Hematology · doi:10.1182/asheducation-2017.1.470 · Cited by 58
Control of mesenchymal stem cell biology by histone modifications
Ren, J., Huang, D., Li, R., Wang, W., & Zhou, C. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-0378-8 · Cited by 54
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
Garbarino, J. M., Eckroate, J., Sundaram, R. K., Jensen, R. B., & Bindra, R. S. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101147 · Cited by 54
Desaulniers, D. M., Vasseur, P., Jacobs, A. C., Aguila, M. C., Ertych, N., & Jacobs, M. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010969 · Cited by 55
Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
Jiang, H., Greathouse, R. L., Tiche, S. J., Zhao, M., He, B., Li, Y., Li, A. M., Forgo, B. L., Yip, M., Li, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1029 · Cited by 50
The role of mitochondria in the oncogenic signal transduction
Frezza, C. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.12.013 · Cited by 53
Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers
Ichimura, K., Narita, Y., & Hawkins, C. E. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1439-7 · Cited by 56
KDM4B: A Nail for Every Hammer?
Wilson, C. B., & Krieg, A. J. (2019) · Genes · doi:10.3390/genes10020134 · Cited by 51
Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death
Läsche, M., Emons, G., & Gründker, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00409 · Cited by 55
Li, W., & Zhang, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01834 · Cited by 54
Alterations of 5-Hydroxymethylcytosine in Human Cancers
Mariani, C. J., Madžo, J., Moen, E. L., Yesilkanal, A. E., & Godley, L. A. (2013) · Cancers · doi:10.3390/cancers5030786 · Cited by 53
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia
Gallipoli, P., Giotopoulos, G., & Huntly, B. J. P. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715577614 · Cited by 53
Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy
Bergaggio, E., & Piva, R. (2019) · Cancers · doi:10.3390/cancers11040563 · Cited by 52
Grabek, J., Straube, J., Bywater, M. J., & Lane, S. (2020) · Cells · doi:10.3390/cells9081901 · Cited by 60
RNA modifications in hematopoietic malignancies: a new research frontier
Qing, Y., Su, R. J., & Chen, J. (2021) · Blood · doi:10.1182/blood.2019004263 · Cited by 51
Metabolism-driven chromatin dynamics: Molecular principles and technological advances
Sahu, V., & Lü, C. (2025) · Molecular Cell · doi:10.1016/j.molcel.2024.12.012 · Cited by 56
20 years of histone lysine demethylases: From discovery to the clinic and beyond
Gray, Z. H., Honer, M. A., Ghatalia, P., Shi, Y., & Whetstine, J. R. (2025) · Cell · doi:10.1016/j.cell.2025.02.023 · Cited by 59
Hypoxia and Metabolism in Cancer
Bensaad, K., & Harris, A. L. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_1 · Cited by 49
Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?
van Lith, S. A. M., Navis, A. C., Verrijp, K. N., Niclou, S. P., Bjerkvig, R., Wesseling, P., Tops, B. B. J., Molenaar, R. J., Noorden, C. J. F. V., & Leenders, W. P. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.004 · Cited by 51
Developmental origins and oncogenic pathways in malignant brain tumors
Lu, Q. R., Qian, L., & Zhou, X. (2019) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.342 · Cited by 55
Xu, J., Shi, Q., Xu, W., Zhou, Q., Shi, R., Ma, Y., Chen, D., Zhu, L., Feng, L., Cheng, A. S. L., et al. (2019) · Theranostics · doi:10.7150/thno.31301 · Cited by 51
Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers
Bledea, R., Vasudevaraja, V., Patel, S. V., Stafford, J. M., Serrano, J., Esposito, G., Tredwin, L. M., Goodman, N. E., Kloetgen, A., Golfinos, J. G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53262-7 · Cited by 52
Crosstalk Between Staphylococcus aureus and Innate Immunity: Focus on Immunometabolism
Horn, C. M., & Kielian, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.621750 · Cited by 53
Dinardo, C. D., Roboz, G. J., Watts, J. M., Madanat, Y. F., Prince, G. T., Baratam, P., de Botton, S., Stein, A. S., Foran, J. M., Arellano, M. L., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012302 · Cited by 50
Exploring metabolic pathways that contribute to the stem cell phenotype
Vacanti, N. M., & Metallo, C. M. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.08.007 · Cited by 51
Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas
Hsieh, K. L., Chen, C., & Lo, C. (2017) · Oncotarget · doi:10.18632/oncotarget.17585 · Cited by 50
NMR and MS-based Stable Isotope-Resolved Metabolomics and applications in cancer metabolism
Lane, A. N., Higashi, R. M., & Fan, T. W. ‐. (2018) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2018.11.020 · Cited by 52
Lin, J., Lu, W., Caravella, J. A., Campbell, A. M., Diebold, R. B., Ericsson, A. M., Fritzen, E. L., Gustafson, G. R., Lancia, D. R., Shelekhin, T. E., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00362 · Cited by 51
A map of the altered glioma metabolism
Deshmukh, R. S., Allega, M. F., & Tardito, S. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.07.011 · Cited by 53
Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma
Broit, N., Johansson, P. A., Rodgers, C. B., Walpole, S., Newell, F., Hayward, N. K., & Pritchard, A. L. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0839 · Cited by 55
An Overview of Targeted Therapies in Acute Myeloid Leukemia
Turkalj, S., Radtke, F. A., & Vyas, P. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000914 · Cited by 54
Schvartzman, J. M., Forsyth, G., Walch, H. S., Chatila, W. K., Taglialatela, A., Lee, B. J., Zhu, X., Gershik, S., Cimino, F. V., Santella, A., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.05.026 · Cited by 53
Self-citationGatekeepers of chromatin: Small metabolites elicit big changes in gene expression
Kaochar, S., & Tu, B. P. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.07.008 · Cited by 49
Novel Therapeutic Targets of Tumor Metabolism
Kishton, R. J., & Rathmell, J. C. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000099 · Cited by 48
Ofran, Y., & Rowe, J. M. (2012) · British Journal of Haematology · doi:10.1111/bjh.12135 · Cited by 51
Gunn, K., Myllykoski, M., Cao, J. Z., Ahmed, M., Huang, B., Rouaisnel, B., Diplas, B. H., Levitt, M. M., Looper, R., Doench, J. G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0825 · Cited by 57
Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia
Fathi, A. T., Wander, S. A., Faramand, R. G., & Emadi, A. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.002 · Cited by 48
FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH1 expression
Charitou, P., Colman, M. J. R., Gerrits, J., van Triest, M. H., Koerkamp, M. J. A. G., Hornsveld, M., Holstege, F. C. P., Verhoeven‐Duif, N. M., & Burgering, B. M. T. (2015) · EMBO Reports · doi:10.15252/embr.201439096 · Cited by 47
Glutamine at focus: versatile roles in cancer
Vitto, H. D., Pérez-Valencia, J. A., & Radosevich, J. A. (2015) · Tumor Biology · doi:10.1007/s13277-015-4671-9 · Cited by 54
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate
Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A., Goparaju, R., Schwarzer, A., Görlich, K., Schottmann, R., Struys, E. A., Jansen, E. E. W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.71 · Cited by 50
Epigenetic regulators and their impact on therapy in acute myeloid leukemia
Pastore, F., & Levine, R. L. (2016) · Haematologica · doi:10.3324/haematol.2015.140822 · Cited by 49
Self-citationMetabolic reprogramming in the pathogenesis of glioma: Update
Masui, K., Onizuka, H., Cavenee, W. K., Mischel, P. S., & Shibata, N. (2019) · Neuropathology · doi:10.1111/neup.12535 · Cited by 48
Krichevsky, A. M., & Uhlmann, E. J. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00702-3 · Cited by 48
Oncometabolites in cancer aggressiveness and tumour repopulation
Dando, I., Pozza, E. D., Ambrosini, G., Torrens‐Mas, M., Butera, G., Mullappilly, N., Pacchiana, R., Palmieri, M., & Donadelli, M. (2019) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12513 · Cited by 49
Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells
Xu, X., Wang, L., Hu, L., Dirks, W. G., Zhao, Y., Wei, Z., Chen, D., Li, Z., Wang, Z., Han, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32552 · Cited by 49
Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation
van Gils, N., Verhagen, H. J. M. P., & Smit, L. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.007 · Cited by 49
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Fruchtman, H., Avigan, Z. M., Waksal, J. A., Brennan, N., & Mascarenhas, J. O. (2024) · Leukemia · doi:10.1038/s41375-024-02246-2 · Cited by 59
Misumi, K., Hayashi, A., Shibahara, J., Arita, J., Sakamoto, Y., Hasegawa, K., Kokudo, N., & Fukayama, M. (2016) · Histopathology · doi:10.1111/his.13127 · Cited by 47
The Effect of Molecular Diagnostics on the Treatment of Glioma
Bush, N. A. O., & Butowski, N. A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0585-6 · Cited by 47
Ali, S. M., Yao, M., Yao, J., Wang, J., Cheng, Y., Schrock, A. B., Chirn, G., Chen, H., Mu, S., Gay, L. M., et al. (2017) · Cancer · doi:10.1002/cncr.30781 · Cited by 47
Zhang, W., Zhang, M., Gao, C., Zhang, Y., Ge, Y., Guo, S., Guo, X., Zhou, Z., Liu, Q., Zhang, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619034114 · Cited by 47
Suzuki, T., Komatsu, T., Shibata, H., Tanioka, A., Vargas, D., Kawabata‐Iwakawa, R., Miura, F., Masuda, S., Hayashi, M., Tanimura-Inagaki, K., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad342 · Cited by 47
Writers, Readers, and Erasers of Epigenetic Marks
Nicholson, T. B., Veland, N., & Chen, T. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800206-3.00003-3 · Cited by 49
Glial Progenitors as Targets for Transformation in Glioma
Ilkhanizadeh, S., Lau, J., Huang, M., Foster, D. J., Wong, R. A., Frantz, A., Wang, S., Weiss, W. A., & Persson, A. I. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00001-9 · Cited by 47
Rakheja, D., Medeiros, L. J., Bevan, S., & Chen, W. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00169 · Cited by 47
IDH1/IDH2but NotTP53Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
Stancheva, G. S., Goranova, T., Laleva, M., Kamenova, M. A., Mitkova, A. V., Velinov, N., Poptodorov, G., Mitev, V., Kaneva, R. P., & Gabrovsky, N. (2014) · BioMed Research International · doi:10.1155/2014/654727 · Cited by 46
Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling
Gao, P., Yang, C., Nesvick, C. L., Feldman, M. J., Sizdahkhani, S., Liu, H., Chu, H., Yang, F., Tang, L., Tian, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7710 · Cited by 45
Waitkus, M. S., Pirozzi, C. J., Moure, C. J., Diplas, B. H., Hansen, L. J., Carpenter, A. B., Yang, R. R., Wang, Z., Ingram, B. O., Karoly, E. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1352 · Cited by 48
Madala, H. R., Punganuru, S. R., Arutla, V., Misra, S., Thomas, T., & Srivenugopal, K. S. (2018) · Cancers · doi:10.3390/cancers10020049 · Cited by 46
Ulanet, D., Couto, K., Jha, A., Choe, S. E., Wang, Y., Woo, H.-K., Steadman, M., DeLaBarre, B., Größ, S., Driggers, E. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115144 · Cited by 49
Post-translational modifications on mitochondrial metabolic enzymes in cancer
Peng, Y., Liu, H., Liu, J., & Long, J. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.12.264 · Cited by 49
How I treat with maintenance therapy after allogeneic HCT
DeFilipp, Z. M., & Chen, Y. (2022) · Blood · doi:10.1182/blood.2021012412 · Cited by 45
Iron drives anabolic metabolism through active histone demethylation and mTORC1
Shapiro, J. S., Chang, H., Tatekoshi, Y., Zhao, Z., Waxali, Z. S., Hong, B. J., Chen, H., Geier, J., Bartom, E. T., Jesus, A. D., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01225-6 · Cited by 45
Metabolite regulation of epigenetics in cancer
Wang, P., Chen, L., Xiong, Y., & Ye, D. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114815 · Cited by 50
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma
Birner, P., Pusch, S., Christov, C., Mihaylova, S., Toumangelova‐Uzeir, K., Natchev, S., SCHOPPMANN, S. F., Tchorbanov, A. I., Streubel, B., Tuettenberg, J., et al. (2014) · Cancer · doi:10.1002/cncr.28732 · Cited by 46
Suijker, J., Baelde, H. J., Roelofs, H., Cleton-Jansen, A., & Bovée, J. V. M. G. (2015) · Oncotarget · doi:10.18632/oncotarget.4024 · Cited by 47
Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment
Haynes, H. R., Camelo-Piragua, S. I., & Kurian, K. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00047 · Cited by 45
Research into cancer metabolomics: Towards a clinical metamorphosis
Olivares, O., Däbritz, J. H. M., King, A., Gottlieb, E., & Halsey, C. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.008 · Cited by 45
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma
Fathi, A. T., Nahed, B. V., Wander, S. A., Iafrate, A. J., Borger, D. R., Hu, R., Thabet, A., Cahill, D. P., Perry, A. M., Joseph, C. P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0342 · Cited by 46
Evolving Molecular Genetics of Glioblastoma
Li, Q.-J., Cai, J., & Liu, C.-Y. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.176065 · Cited by 47
ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors
Cai, J., Zhang, C., Zhang, W., Wang, G., Yao, K., Wang, Z., Li, G., Qian, Z., Li, Y., Jiang, T., et al. (2016) · Oncoscience · doi:10.18632/oncoscience.317 · Cited by 46
Badur, M. G., & Metallo, C. M. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.11.013 · Cited by 44
Viswanath, P., Radoul, M., Izquierdo-García, J. L., Luchman, H. A., Cairncross, J. G., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0178-3 · Cited by 48
Unruh, D. J., Mirkov, S., Wray, B. D., Drumm, M. R., Lamano, J. B., Li, Y. D., Haider, Q. F., Javier, R., McCortney, K., Saratsis, A. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1222 · Cited by 44
Bunse, L., Rupp, A.-K., Poschke, I. C., Bunse, T., Lindner, K. A. M., Wick, A., Blobner, J., Misch, M., Tabatabai, G., Glas, M., et al. (2022) · Neurological Research and Practice · doi:10.1186/s42466-022-00184-x · Cited by 45
Klink, B., Miletić, H., Stieber, D., Huszthy, P. C., Valenzuela, J. A. C., Balß, J., Wang, J., Schubert, M., Sakariassen, P. Ø., Sundstrøm, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059773 · Cited by 44
Action at a Distance: Allostery and the Development of Drugs to Target Cancer Cell Metabolism
DeLaBarre, B., Hurov, J., Cianchetta, G., Murray, S., & Dang, L. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.007 · Cited by 45
Mur, P., Mollejo, M., Hernández‐Iglesias, T., de Lope, Á. R., Castresana, J. S., García, J. F., Fiaño, C., Ribalta, T., REY, J. A., & Meléndez, B. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000167 · Cited by 45
Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis
Ballabio, E., & Milne, T. A. (2012) · Cancers · doi:10.3390/cancers4030904 · Cited by 46
Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time
Filbin, M. G., & Suvà, M. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044208 · Cited by 46
Tarhonskaya, H., Nowak, R. P., Johansson, C., Szykowska, A., Tumber, A., Hancock, R. L., Lang, P. A., Flashman, E., Oppermann, U. C. T., Schofield, C. J., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.08.007 · Cited by 45
Metadata
- Authors
- Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., Wellen, K. E., O’Rourke, D. M., Berger, S. L., Chan, T. A., Levine, R. L., Mellinghoff, I. K., & Thompson, C. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Pennsylvania (US)
- Weill Cornell Medicine (US)
- Corresponding author
- Thompson, Craig B.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 474-478
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3478770
- OpenAlex
- W2154313451
- Cited by
- 1,985
- References
- 30
- Citations by year
- 2026: 81 · 2025: 93 · 2024: 106 · 2023: 125 · 2022: 122 · 2021: 180 · 2020: 170 · 2019: 153 · 2018: 146 · 2017: 163 · 2016: 151 · 2015: 123 · 2014: 138 · 2013: 136 · 2012: 91
- FWCI
- 74.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- National Cancer Institute (R01CA078831, R01CA105463, U54CA143798)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- 2-hydroxyglutarate, histone demethylation, histone methylation, glioma, oncometabolites, DNA hypermethylation, hypoxia-inducible factor, adipogenesis, neural progenitor cells
- MeSH terms
- Animals, Astrocytes, Cell Differentiation, Enzyme Induction, Gene Expression Regulation, Glioma, Glutarates, Histones, Humans, Isocitrate Dehydrogenase, Methylation, Mutation, Promoter Regions, Genetic, Adipocytes, Cell Lineage, DNA Methylation, 3T3-L1 Cells, Cell Line, Tumor, Mice, Jumonji Domain-Containing Histone Demethylases, HEK293 Cells, Neural Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
